Melanoma & Renal Cancer

By receiving your generous support CTRT can run a comprehensive program of clinical trials for patients with melanoma and renal cancer. This allows our patients access to the most modern treatments whilst also improving our understanding of the diseases we treat and identification of opportunities to improve outcomes. 

The research team is led by Dr Paul Nathan (melanoma and renal cancer), Dr Heather Shaw (melanoma) and Dr Anand Sharma (renal cancer). We have a dedicated team that run all aspects of clinical trials from patient care to data management. However 80% of their salaries are covered by charitable funds and commercial trial income, only one salary is received from the national cancer research network. Our patients, therefore, have access to the most innovative treatments because of the generosity of contributors to CTRT.

Renal Cancer

Dr Anand Sharma

Dr Paul Nathan

Patients now have the opportunity to access clinical trials in the adjuvant (following surgery) and advanced disease settings. Many of our studies are attempting to identify and improve ways to stimulate an effective immune response to the cancer.  These results will hope to aid an attempt to gain long term control of the disease.


Dr Paul Nathan

Gut Microbiome Study

(PRIMM – Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics.)

There is increasing evidence that the population of bugs that live in our guts. The gut called microbiome can profoundly influence how our immune system responds to cancer. PRIMM is an international, collaborative study led by Dr Nathan, a consultant dermatologist Dr Dr.Veronique Bataille and Professor Tim Spector at King’s College. Together they are looking at the influence of the gut microbiome on the effectiveness and toxicity of immunotherapy in melanoma patients.

CTRT supports a research fellow, Karla Loudon, and a research assistant, Simran Sumal on the PRIMM study. Karla has registered for her PhD and is doing excellent work on the association between microbiome and outcomes in the PRIMM cohort. The study has a high international impact and major publications are starting to be delivered.

Uveal Melanoma

Melanoma can rarely start in the back of the eye. However, uveal melanoma is distinct from skin melanoma and is usually associated with particularly poor outcomes.

We have been leading the clinical development of a novel immunotherapy drug called Tebentafusp. Dr Nathan is the chief investigator on the recently completed phase III study and the whole CTRT supported study team has been very involved. As there were only two UK sites patients travelled from many parts of the country to come to Mount Vernon. Fortunately, we have shown that the drug significantly improves survival in patients with advanced disease. Immunocore is a company that has developed the drug are applying for licences with regulatory authorities worldwide because of this data.

Back to our research